JP2023504744A5 - - Google Patents

Info

Publication number
JP2023504744A5
JP2023504744A5 JP2022534195A JP2022534195A JP2023504744A5 JP 2023504744 A5 JP2023504744 A5 JP 2023504744A5 JP 2022534195 A JP2022534195 A JP 2022534195A JP 2022534195 A JP2022534195 A JP 2022534195A JP 2023504744 A5 JP2023504744 A5 JP 2023504744A5
Authority
JP
Japan
Prior art keywords
sequence
seq
rnai construct
construct according
sequence number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022534195A
Other languages
English (en)
Japanese (ja)
Other versions
JP7827623B2 (ja
JP2023504744A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063844 external-priority patent/WO2021119034A1/en
Publication of JP2023504744A publication Critical patent/JP2023504744A/ja
Publication of JP2023504744A5 publication Critical patent/JP2023504744A5/ja
Application granted granted Critical
Publication of JP7827623B2 publication Critical patent/JP7827623B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022534195A 2019-12-09 2020-12-08 ＬＰＡ発現を阻害するためのＲＮＡｉコンストラクト及び方法 Active JP7827623B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945777P 2019-12-09 2019-12-09
US62/945,777 2019-12-09
PCT/US2020/063844 WO2021119034A1 (en) 2019-12-09 2020-12-08 RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION

Publications (3)

Publication Number Publication Date
JP2023504744A JP2023504744A (ja) 2023-02-06
JP2023504744A5 true JP2023504744A5 (https=) 2023-12-13
JP7827623B2 JP7827623B2 (ja) 2026-03-10

Family

ID=74141837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534195A Active JP7827623B2 (ja) 2019-12-09 2020-12-08 ＬＰＡ発現を阻害するためのＲＮＡｉコンストラクト及び方法

Country Status (7)

Country Link
US (1) US20230078200A1 (https=)
EP (1) EP4073252A1 (https=)
JP (1) JP7827623B2 (https=)
AU (1) AU2020399636A1 (https=)
CA (1) CA3163322A1 (https=)
MX (1) MX2022007005A (https=)
WO (1) WO2021119034A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12435336B2 (en) * 2020-08-05 2025-10-07 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting LPA expression
WO2022121959A1 (zh) * 2020-12-09 2022-06-16 纳肽得有限公司 siRNA分子及其在治疗冠状动脉疾病中的应用
WO2023041508A2 (en) * 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
WO2023041079A1 (zh) * 2021-09-18 2023-03-23 上海金中锘美生物医药科技有限公司 Lpa抑制剂及其用途
IL312811A (en) 2021-11-16 2024-07-01 Shanghai Argo Biopharmaceutical Co Ltd Composition and method for inhibiting angiotensinogen (agt) protein expression
TW202345865A (zh) * 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
CN120322552A (zh) * 2022-07-27 2025-07-15 e-生物有限公司 核酸化合物
KR20250088573A (ko) * 2022-10-14 2025-06-17 사네진 바이오 유에스에이 인크. C3을 표적화하는 소형 간섭 rna 및 그의 용도
EP4630555A2 (en) * 2022-12-05 2025-10-15 Eli Lilly And Company Modified oligonucleotides
AU2023408479A1 (en) * 2022-12-19 2025-05-01 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar)
WO2024138105A1 (en) * 2022-12-23 2024-06-27 Eli Lilly And Company Novel rna therapeutics and uses thereof
CN120457209A (zh) * 2022-12-23 2025-08-08 伊莱利利公司 新型rna治疗剂及其用途
WO2024210530A1 (en) * 2023-04-03 2024-10-10 Olix Pharmaceuticals, Inc. RNAi AGENTS TARGETING LPA GENE AND USE THEREOF
WO2024222686A1 (zh) * 2023-04-24 2024-10-31 上海京新生物医药有限公司 用于抑制LPA表达的RNAi剂及其应用
AU2024269205A1 (en) * 2023-05-11 2025-12-11 Keymed Biosciences (Us) Inc. Dsrna molecules for regulating masp2 gene activity
WO2024260380A1 (zh) * 2023-06-20 2024-12-26 施能康医药科技(苏州)有限公司 靶向脂蛋白a的核酸及其用途
KR20260034652A (ko) 2023-07-04 2026-03-13 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 LP(a) 유전자 발현을 억제하기 위한 dsRNA 분자 및 그 용도
TW202540420A (zh) * 2023-11-15 2025-10-16 大陸商北京加科瑞康醫藥科技有限公司 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
CN117805370B (zh) * 2023-12-29 2025-11-04 深圳市新产业生物医学工程股份有限公司 胶乳免疫比浊的检测试剂、试剂盒及检测方法
WO2026006275A2 (en) 2024-06-26 2026-01-02 Amgen Inc. Rnai constructs and methods for inhibiting expression of inhbe
WO2026026811A1 (zh) * 2024-07-29 2026-02-05 成都先衍生物技术有限公司 一种具有双靶点基因抑制作用的核酸缀合物及其应用
WO2026026812A1 (zh) * 2024-07-29 2026-02-05 成都先衍生物技术有限公司 一种具有双靶点基因抑制作用的核酸缀合物及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5976567A (en) 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
CA2685127C (en) 2007-04-23 2019-01-08 Alnylam Pharmaceuticals, Inc. Glycoconjugates of rna interference agents
WO2009073809A2 (en) 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
EP3564374A1 (en) 2013-06-21 2019-11-06 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
JOP20160211B1 (ar) 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
HRP20230127T1 (hr) * 2017-11-13 2023-03-31 Silence Therapeutics Gmbh Nukleinske kiseline za inhibiranje ekspresije lpa u stanici
UY38003A (es) * 2017-12-12 2019-06-28 Amgen Inc Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
WO2020123410A1 (en) * 2018-12-10 2020-06-18 Amgen Inc. CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF

Similar Documents

Publication Publication Date Title
JP2023504744A5 (https=)
JP2023537943A5 (https=)
JP2022511866A5 (https=)
TWI784934B (zh) 抑制lpa之基因表現之組合物及方法
JP2019214587A5 (https=)
JP2021521796A5 (https=)
JP2023103244A5 (https=)
JP6060178B2 (ja) 高効率のナノ粒子型二本鎖オリゴｒｎａ構造体およびその製造方法
JP2021006029A5 (https=)
JP2024105284A5 (https=)
JP2019122379A (ja) 細胞内貫通能を持ってｒｎａ干渉を誘導する核酸分子およびその用途
JP2011511636A5 (https=)
JP2009514877A5 (https=)
JP2008527993A (ja) 特異性及び送達の改善のためのｓｉＲＮＡ分子、ｓｈＲＮＡ分子又はアンチセンス分子及び機能的実体を含む複合体
JP2022511550A5 (https=)
CA3189861A1 (en) Dux4 inhibitors and methods of use thereof
CN118440938B (zh) 一种靶向AGT基因表达的siRNA及其缀合物和用途
JP2020529197A5 (https=)
WO2012094586A2 (en) Synthetic non-covalently self-assembling bipartite prna chimeras
JP2026500220A (ja) 高度ｒｎａ標的化（ａｒｎａｔａｒ）
AU2019271311B2 (en) Methods for treating VEGF-related conditions
WO2024164008A1 (en) Products and compositions
JP2025512771A5 (https=)
JP2024539097A5 (https=)
KR20260016935A (ko) 안지오텐시노겐을 표적으로 하는 핵산 및 이의 용도